[go: up one dir, main page]

EP1171147A4 - Modulation of excitable tissue function by peripherally administered erythropoietin - Google Patents

Modulation of excitable tissue function by peripherally administered erythropoietin

Info

Publication number
EP1171147A4
EP1171147A4 EP00923344A EP00923344A EP1171147A4 EP 1171147 A4 EP1171147 A4 EP 1171147A4 EP 00923344 A EP00923344 A EP 00923344A EP 00923344 A EP00923344 A EP 00923344A EP 1171147 A4 EP1171147 A4 EP 1171147A4
Authority
EP
European Patent Office
Prior art keywords
modulation
tissue function
excitable tissue
peripherally administered
administered erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00923344A
Other languages
German (de)
French (fr)
Other versions
EP1171147A1 (en
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warren Kenneth S Institute Inc
Original Assignee
Warren Kenneth S Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Kenneth S Institute Inc filed Critical Warren Kenneth S Institute Inc
Publication of EP1171147A1 publication Critical patent/EP1171147A1/en
Publication of EP1171147A4 publication Critical patent/EP1171147A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00923344A 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin Ceased EP1171147A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US290938 1989-01-04
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11
US547220 2000-04-11
PCT/US2000/010019 WO2000061164A1 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Publications (2)

Publication Number Publication Date
EP1171147A1 EP1171147A1 (en) 2002-01-16
EP1171147A4 true EP1171147A4 (en) 2003-05-14

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00923344A Ceased EP1171147A4 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Country Status (21)

Country Link
EP (1) EP1171147A4 (en)
JP (1) JP2003520194A (en)
KR (2) KR101012932B1 (en)
CN (1) CN1607957B (en)
AU (1) AU784550B2 (en)
BG (1) BG65353B1 (en)
BR (1) BR0009737A (en)
CA (1) CA2383940A1 (en)
CR (1) CR6501A (en)
CZ (1) CZ20013695A3 (en)
EA (1) EA004766B1 (en)
HU (1) HUP0201598A3 (en)
IL (2) IL145895A0 (en)
IS (1) IS6104A (en)
MX (1) MXPA01010177A (en)
NO (1) NO20014991L (en)
NZ (4) NZ560696A (en)
PL (1) PL352223A1 (en)
SK (1) SK14412001A3 (en)
TR (2) TR200103785T2 (en)
WO (1) WO2000061164A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2003089468A1 (en) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US8039253B2 (en) 2000-06-30 2011-10-18 Tokyo Metropolitan Institute Of Gerontology Pharmaceutical for prevention and treatment of demyelinating disease
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1471871B1 (en) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ATE542904T1 (en) 2001-10-29 2012-02-15 Crucell Holland Bv METHOD AND MEANS FOR PRODUCING PROTEINS WITH PREDEFINED POST-TRANSLATIONAL MODIFICATIONS
DE60224843T2 (en) 2001-12-07 2009-01-08 Crucell Holland B.V. Production of viruses, virus and vaccines
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (en) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
CA2519803A1 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica N.V. Use of erythropoietin in stroke recovery
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN100383238C (en) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004063927A1 (en) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
BRPI0614529A8 (en) * 2005-08-05 2016-07-12 Warren Pharmaceuticals Inc isolated polypeptide, pharmaceutical composition, method for protecting, maintaining or enhancing the viability of an isolated responsive cell, tissue or organ of the mammalian body, use of an isolated polypeptide, method for facilitating transcytosis of a molecule, isolated nucleic acid, vector, host cell, and method for recombinantly producing the isolated polypeptide
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
KR20180123731A (en) 2008-01-22 2018-11-19 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2519695C2 (en) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury
WO2000035475A2 (en) * 1998-12-14 2000-06-22 Hannelore Ehrenreich Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury
WO2000035475A2 (en) * 1998-12-14 2000-06-22 Hannelore Ehrenreich Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BELAYEV L ET AL: "Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.", BRAIN RESEARCH 23 MAR 1998 LNKD- PUBMED:9518648, vol. 787, no. 2, 23 March 1998 (1998-03-23), pages 277 - 285, ISSN: 0006-8993 *
BERNAUDIN M ET AL: "A POTENTIAL ROLE FOR ERYTHROPOIETIN IN FOCAL PERMANENT CEREBRAL ISCHEMIA IN MICE", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, RAVEN PRESS, LTD., NEW YORK, NY, US, no. 19, 1999, pages 643 - 651, XP002945970, ISSN: 0271-678X *
CAMPANA-WM ET AL.: "Identification of a neurotrophic sequence in erythropoietin", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 1, no. 1, 1998, pages 235 - 241, XP001064780 *
CENGIZ K ET AL: "Does erythropoietin cause epilepsy.", NEPHRON 1996 LNKD- PUBMED:8773367, vol. 73, no. 2, 1996, pages 320 - 321, ISSN: 0028-2766 *
FRIDEN P M: "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1-2, 5 May 1997 (1997-05-05), pages 117 - 128, XP004096317, ISSN: 0168-3659 *
HENGEMIHLE J M ET AL: "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice.", PHYSIOLOGY & BEHAVIOR JAN 1996 LNKD- PUBMED:8848475, vol. 59, no. 1, January 1996 (1996-01-01), pages 153 - 156, ISSN: 0031-9384 *
KANG Y-S ET AL: "PHARMACOKINETICS AND SATURABLE BLOOD-BRAIN BARRIER TRANSPORT OF BIOTIN BOUND TO A CONJUGATE OF AVIDIN AND A MONOCLONAL ANTIBODY TO THE TRANSFERRIN RECEPTOR", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 22, no. 1, 1994, pages 99 - 105, XP002933514, ISSN: 0090-9556 *
MARTI H H ET AL: "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 51, no. 2, February 1997 (1997-02-01), pages 416 - 418, XP001064793, ISSN: 0085-2538 *
MIELKE J G ET AL: "Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.", NEUROSCIENCE LETTERS 23 MAY 1997 LNKD- PUBMED:9185677, vol. 227, no. 3, 23 May 1997 (1997-05-23), pages 169 - 172, ISSN: 0304-3940 *
MINNERUP-J ET AL.: "EPO for stroke therapy - Is there a future for furtherclinical development?", EXPERIMENTAL & TRANSLATIONAL STROKE MEDICINE, vol. 2, no. 10, DOI: 10.1186/2040-7378-2-10 *
PAN W ET AL: "Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha.", THE AMERICAN JOURNAL OF PHYSIOLOGY OCT 1996 LNKD- PUBMED:8897850, vol. 271, no. 4 Pt 1, October 1996 (1996-10-01), pages E636 - E642, ISSN: 0002-9513 *
PARDRIDGE W M: "CNS DRUG DESIGN BASED ON PRINCIPLES OF BLOOD-BRAIN BARRIER TRANSPORT", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 70, no. 5, May 1998 (1998-05-01), pages 1782 - 1792, XP000885629, ISSN: 0022-3042 *
S. PARK, P. SINKO: "Characterization of Biotin Transport across the Blood-Brain Barrier in Mice and Correlation with In Vitro Data", THE AAPS JOURNAL, vol. 6, no. S1, 2004, Retrieved from the Internet <URL:http://www.aapsj.org/abstracts/AM_2004/AAPS2004-002913.PDF> *
SAKANAKA M ET AL: "In vivo evidence that erythropoietin protects neurons from ischemic damage", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, April 1998 (1998-04-01), pages 4635 - 4640, XP002142085, ISSN: 0027-8424 *
See also references of WO0061164A1 *
SHI F ET AL: "Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers.", PHARMACEUTICAL RESEARCH FEB 1993 LNKD- PUBMED:8456078, vol. 10, no. 2, February 1993 (1993-02-01), pages 282 - 288, ISSN: 0724-8741 *
SØLLING-C ET AL.: "Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia.", ACTA ANAESTHESIOL SCAND - PUBLICATON AHEAD OF PRINT, 22 February 2011 (2011-02-22), DOI: 10.1111/J.1399-6576.2011.02396.X. *
SQUADRITO F ET AL: "Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.", BRITISH JOURNAL OF PHARMACOLOGY MAY 1999 LNKD- PUBMED:10385249, vol. 127, no. 2, 1 January 1999 (1999-01-01) - May 1999 (1999-05-01), pages 482 - 488, ISSN: 0007-1188 *
WHALEN M J ET AL: "Blood-brain barrier permeability, neutrophil accumulation and vascular adhesion molecule expression after controlled cortical impact in rats: a preliminary study.", ACTA NEUROCHIRURGICA. SUPPLEMENT 1998 LNKD- PUBMED:9779187, vol. 71, 1998, pages 212 - 214, ISSN: 0065-1419 *
ZHOU QING-HUI ET AL: "Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.", MOLECULAR PHARMACEUTICS 6 DEC 2010 LNKD- PUBMED:20860349, vol. 7, no. 6, 6 December 2010 (2010-12-06), pages 2148 - 2155, ISSN: 1543-8392 *

Also Published As

Publication number Publication date
HUP0201598A2 (en) 2002-09-28
KR20070094997A (en) 2007-09-27
TR200402194T2 (en) 2004-10-21
CR6501A (en) 2004-04-15
JP2003520194A (en) 2003-07-02
IS6104A (en) 2001-10-11
NO20014991D0 (en) 2001-10-12
IL145895A0 (en) 2002-07-25
CN1607957A (en) 2005-04-20
KR101012932B1 (en) 2011-02-08
AU4348700A (en) 2000-11-14
KR100883232B1 (en) 2009-02-10
HUP0201598A3 (en) 2002-10-28
KR20020000874A (en) 2002-01-05
NZ560696A (en) 2010-03-26
NZ533098A (en) 2006-04-28
TR200103785T2 (en) 2002-06-21
MXPA01010177A (en) 2004-09-10
EP1171147A1 (en) 2002-01-16
EA004766B1 (en) 2004-08-26
AU784550B2 (en) 2006-05-04
CA2383940A1 (en) 2000-10-19
NO20014991L (en) 2001-11-15
CZ20013695A3 (en) 2002-02-13
NZ545478A (en) 2008-04-30
SK14412001A3 (en) 2002-03-05
NZ514690A (en) 2004-07-30
IL145895A (en) 2010-05-31
EA200101073A1 (en) 2002-10-31
BR0009737A (en) 2003-01-14
CN1607957B (en) 2012-10-10
BG65353B1 (en) 2008-03-31
PL352223A1 (en) 2003-08-11
WO2000061164A1 (en) 2000-10-19
BG106058A (en) 2002-12-29

Similar Documents

Publication Publication Date Title
PL352223A1 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
GB2357774B (en) Biioabsorbable cyanoacrylate tissue adhesives
AU2560099A (en) Single-use syringe
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
PL351261A1 (en) Derivatives of indigoid bisindoles
AU7362400A (en) Occlusion of tubular anatomical structures by energy application
AU6506698A (en) Tissue implant
PL350854A1 (en) Intermittent substitutive hormonoal therapy with low doswe of oestrogen
ZA200107122B (en) Treatment of acne using lipoic acid.
GB0001140D0 (en) Microgradient intensity modulating multi-leaf collimator r
AU7960800A (en) X-ray generator of open type
AU3766700A (en) Human tumor necrosis factor receptor-like 2
AU6115400A (en) Antisense modulation of mekk5 expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU1878201A (en) Composition for the treatment of damaged tissue
AU2501200A (en) Human peptidases
AU1921100A (en) Antisense modulation of smad4 expression
AU5394300A (en) Tissue engineering
ZA200108407B (en) Modulation of excitable tissue function by peripherally administered erythropoietin.
AU5874800A (en) Antisense modulation of ets-2 expression
AU5615700A (en) Antisense modulation of g-alpha-i2 expression
AU1489701A (en) Antisense modulation of nck-2 expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030328

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/18 K

Ipc: 7A 61K 31:00 K

Ipc: 7A 61K 38:00 J

Ipc: 7A 61P 37/00 B

Ipc: 7A 61K 38/18 J

Ipc: 7A 61K 47/48 B

Ipc: 7A 61K 38/18 B

Ipc: 7C 07K 14/00 B

Ipc: 7A 61K 38/00 A

Ipc: 7A 61P 27/00 B

Ipc: 7A 61P 25/00 B

17Q First examination report despatched

Effective date: 20040319

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20111014